Emerging therapy targeting tyrosine-protein kinase BTK: Potential for ibrutinib and other BTK inhibitors

Drugs of the Future

Volumn 38, Issue 8, 2013, Pages 569-573

  MacEwan, David J ^a   Bowles, K M ^b   Rushworth, S A ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Autoimmune disease; Hematological cancer; Leukemia; Lymphoma; Multiple myeloma; Small molecule inhibitor; Tyrosine protein kinase BTK

Indexed keywords

AVL 292; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CC 292; HM 71224; IBRUTINIB; ONO 4059; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BONE MARROW TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; LUPUS ERYTHEMATOSUS; LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84930538669     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.08.1998163     Document Type: Review

References (45)

1. Buckley, C.R. Agammaglobulinemia, by Col. Ogden C. Bruton, MC, USA, Pediatrics, 1952;9:722-728.
2. Pediatrics 1998, 102(1, Pt. 2): 213-5.
3. Honda, F., Kano, H., Kanegane, H. et al. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol 2012, 13(4): 369-78.
4. Conley, M.E., Farmer, D.M., Dobbs, A.K., Howard, V., Aiba, Y., Shurtleff, S.A., Kurosaki, T. A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease. Clin Exp Immunol 2008, 152(1): 39-44.
5. Saito, K., Scharenberg, A.M., Kinet, J.P. Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk. J Biol Chem 2001, 276(19): 16201-6.
6. Salim, K., Bottomley, M.J., Querfurth, E. et al. Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. EMBO J 1996, 15(22): 6241-50.
7. Rawlings, D.J., Saffran, D.C., Tsukada, S. et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993, 261(5119): 358-61.
8. Pauls, S.D., Lafarge, S.T., Landego, I., Zhang, T., Marshall, A.J. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: Activation mechanisms, regulation and impact on cellular functions. Front Immunol 2012, 3: 224.
9. DeFranco, A.L. Vav and the B cell signalosome. Nat Immunol 2001, 2(6): 482-4.
10. Samuels, J., Ng, Y.S., Coupillaud, C., Paget, D., Meffre, E. Human B cell tolerance and its failure in rheumatoid arthritis. Ann N Y Acad Sci 2005, 1062: 116-26.
11. Conley, M.E., Dobbs, A.K., Farmer, D.M. et al. Primary B cell immunodeficiencies: Comparisons and contrasts. Annu Rev Immunol 2009, 27: 199-227.
12. Fruman, D.A., Rommel, C. PI3Kdelta inhibitors in cancer: Rationale and serendipity merge in the clinic. Cancer Discov 2011, 1(7): 562-72.
13. Feldhahn, N., Rio, P., Soh, B.N. et al. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci U S A 2005, 102(37): 13266-71.
14. Pan, Z., Scheerens, H., Li, S.J. et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007, 2(1): 58-61.
15. Ponader, S., Chen, S.S., Buggy, J.J. et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119(5): 1182-9.
16. Honigberg, L.A., Smith, A.M., Sirisawad, M. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010, 107(29): 13075-80.
17. Senior, K. Positive results for ibrutinib in B-cell malignancies. Lancet Oncol 2012, 13(12): e522.
18. Burger, J.A., Buggy, J.J. Emerging drug profiles: Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 2013.
19. Advani, R.H., Buggy, J.J., Sharman, J.P. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31(1): 88-94.
20. O'Brien, S., Furman, R., Coutre, S. et al. The Bruton's tyrosine kinase inhibitor ibrutinib is highly active and tolerable in relapsed or refractory (R/R) and treatment naïve (TN) CLL patients, updated results of a phase IB/II study. Haematologica [17th Cong Eur Hematol Assoc (June 14-17, Amsterdam) 2012] 2012, 97(Suppl. 1 ): Abst 0542.
21. Burger, J.A., Keating, M.J., Wierda, W.G. et al. The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. 54th Annu Meet Am Soc Hematol (ASH) (Dec 8-11, Atlanta) 2012, Abst 187.
22. Burger, J.A., O'Brien, S., Fowler, N. et al. The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): An update on ongoing phase 1 studies. 53th Annu Meet Am Soc Hematol (ASH) (Dec 10-13, San Diego) 2011, Abst 57.
23. Byrd, J.C., Furman, R.R., Coutre, S. et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: New and updated results of 116 patients in a phase Ib/II study. 54th Annu Meet Am Soc Hematol (ASH) (Dec 8-11, Atlanta) 2012, Abst 189.
24. Wan, Y. FDA grants 'Breakthrough Therapy Designation' to ibrutinib for treatment of relapsed or refractory mantle cell lymphoma and Waldenstrom's macroglobulinemia. http://wwwnelmnhsuk/en/NeLMArea/News/2013-February/14/FDA- grants-Breakthrough-Therapy-Designation-to-ibrutinib-for-treatment-of-relapsed- or-refractory-mantle-cell-lymphoma-and-Waldenstroms-macroglobulinemia/2013.
25. Advani, R., Sharman, J.P., Smith, S.M. et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. 46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010, Abst 8012.
26. Study of the Bruton's tyrosine kinase inhibitor in subjects with relapsed or relapsed and refractory multiple myeloma (NCT01478589). ClinicalTrials. gov Web site, July 15, 2013.
27. Muller, S., Sideras, P., Smith, C.I., Xanthopoulos, K.G. Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members. Oncogene 1996, 13(9): 1955-64.
28. de Weers, M., Verschuren, M.C., Kraakman, M.E., Mensink, R.G., Schuurman, R.K., van Dongen, J.J., Hendriks, R.W. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 1993, 23(12): 3109-14.
29. Genevier, H.C., Hinshelwood, S., Gaspar, H.B. et al. Expression of Bruton's tyrosine kinase protein within the B cell lineage. Eur J Immunol 1994, 24(12): 3100-5.
30. Yu, L., Mohamed, A.J., Simonson, O.E. et al. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 2008, 111(9): 4617-26.
31. Mitsiades, C.S., Mitsiades, N., Poulaki, V. et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002, 21(37): 5673-83.
32. Bharti, A.C., Shishodia, S., Reuben, J.M. et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004, 103(8): 3175-84.
33. Rushworth, S.A., Bowles, K.M., Barrera, L.N., Murray, M.Y., Zaitseva, L., MacEwan, D.J. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 2013, 25(1): 106-12.
34. Edwards, C.M., Zhuang, J., Mundy, G.R. The pathogenesis of the bone disease of multiple myeloma. Bone 2008, 42(6): 1007-13.
35. Edwards, C.M. BTK inhibition in myeloma: Targeting the seed and the soil. Blood 2012, 120(9): 1757-9.
36. Tai, Y.T., Chang, B.Y., Kong, S.Y. et al. Bruton tyrosine kinase inhibition is a Novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012, 120(9): 1877-87.
37. Uckun, F.M., Zheng, Y., Cetkovic-Cvrlje, M. et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyanobeta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide (LFMA13), a Novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 2002, 8(5): 1224-33.
38. Sheridan, C. Companies in rapid pursuit of Btk immunokinase. Nat Biotechnol 2012, 30(3): 199-200.
39. Di Paolo, J.A., Huang, T., Balazs, M. et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 2011, 7(1): 41-50.
40. Yasuhiro, T., Yoshizawa, T., Daub, H., Weber, C., Narita, M., Kawabata, K. ONO-WG-307, a Novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways. 103rd Annu Meet Am Assoc Cancer Res (AACR) (March 31-April 4, Chicago) 2012, Abst 2021.
41. Schwamb, J., Feldhaus, V., Baumann, M. et al. B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood 2012, 120(19): 3978-85.
42. Hutcheson, J., Vanarsa, K., Bashmakov, A. et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and endorgan disease in murine lupus. Arthritis Res Ther 2012, 14(6): R243.
43. Chang, B.Y., Thiemann, P., Moore, N. et al. PCPCI-45292, a Novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in mouse models of arthritis. Arthritis Rheum [74th Annu Sci Meet Am Coll Rheumatol (Nov 6-11, Atlanta) 2010] 2010, 62(Suppl. 10): Abst 286.
44. Prieto-Perez, R., Cabaleiro, T., Dauden, E., Abad-Santos, F. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J 2013.
45. Uckun, F.M. Clinical potential of targeting Bruton's tyrosine kinase. Int Rev Immunol 2008, 27(1-2): 43-69.